Literature DB >> 9764558

Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany.

K Wolle1, M Nilius, A Leodolter, W A Müller, P Malfertheiner, W König.   

Abstract

To evaluate the prevalence of resistance among Helicobacter pylori in Germany, the minimum inhibitory concentrations of amoxicillin, tetracycline, clarithromycin, and metronidazole were determined by means of the E test, for 271 Helicobacter pylori isolates cultured from biopsies taken during routine endoscopies in 1996 and 1997. The prevalence of metronidazole resistance was 32.1%, with resistance found more frequently in women (38.5%) than in men (24.4%). Clarithromycin resistance was rare (3.3%). Eight of nine strains resistant to clarithromycin were also resistant to metronidazole. Resistance to either metronidazole or clarithromycin was significantly (P=0.022) higher in patients with duodenal ulcer. No strain was found to be resistant to amoxicillin or tetracycline.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9764558     DOI: 10.1007/bf01691138

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori.

Authors:  T Alarcón; D Domingo; I Sánchez; F Díaz de Rojas; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

2.  [Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area)].

Authors:  B Tillenburg; S Siehoff; T Becker; U Peitz; G Börsch; J Labenz
Journal:  Z Gastroenterol       Date:  1997-03       Impact factor: 2.000

3.  Helicobacter pylori resistance to tetracycline.

Authors:  P D Midolo; M G Korman; J D Turnidge; J R Lambert
Journal:  Lancet       Date:  1996-04-27       Impact factor: 79.321

4.  One-week low-dose triple therapy: new standards for Helicobacter pylori treatment.

Authors:  A Goddard; R Logan
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-01       Impact factor: 2.566

5.  Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands.

Authors:  A A van Zwet; W A de Boer; P M Schneeberger; J Weel; A R Jansz; J C Thijs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

6.  Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori.

Authors:  Y Glupczynski; M Labbé; W Hansen; F Crokaert; E Yourassowsky
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

7.  Impact of metronidazole resistance on the eradication of Helicobacter pylori.

Authors:  L A Noach; W L Langenberg; M A Bertola; J Dankert; G N Tytgat
Journal:  Scand J Infect Dis       Date:  1994

8.  Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.

Authors:  C S Goodwin; B J Marshall; E D Blincow; D H Wilson; S Blackbourn; M Phillips
Journal:  J Clin Pathol       Date:  1988-02       Impact factor: 3.411

9.  Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori.

Authors: 
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

10.  The E test for antimicrobial susceptibility testing of Helicobacter pylori.

Authors:  G Cederbrant; G Kahlmeter; A Ljungh
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

View more
  9 in total

1.  Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan.

Authors:  M Kato; Y Yamaoka; J J Kim; R Reddy; M Asaka; K Kashima; M S Osato; F A El-Zaatari; D Y Graham; D H Kwon
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

2.  Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in Singapore.

Authors:  Jie-Song Hua; Ho Bow; Peng-Yuan Zheng; Yeoh Khay-Guan
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

3.  Clarithromycin resistance in Helicobacter pylori and its clinical relevance.

Authors:  Hua-Xiang Xia; Xue-Gong Fan; Nicholas J Talley
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

4.  Antibiotic susceptibility of Helicobacter pylori clinical isolates: comparative evaluation of disk-diffusion and E-test methods.

Authors:  K K Mishra; S Srivastava; A Garg; A Ayyagari
Journal:  Curr Microbiol       Date:  2006-09-12       Impact factor: 2.188

5.  In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection.

Authors:  Osamu Kamoda; Kinsei Anzai; Jun-ichi Mizoguchi; Masatoshi Shiojiri; Toshiharu Yanagi; Takeshi Nishino; Shigeru Kamiya
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults.

Authors:  Jong Hwa Lee; Ji-Hyun Shin; Im Hwan Roe; Seung Ghyu Sohn; Jung Hun Lee; Geun Ho Kang; Han-Ki Lee; Byeong Chul Jeong; Sang Hee Lee
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 7.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

8.  Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population.

Authors:  Sook-Yin Lui; Khay-Guan Yeoh; Bow Ho
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

9.  Evaluation of the benefit of addition of clidinium C to a Helicobacter pylori eradication regimen.

Authors:  Maryam Chorami; Homayoun Zojaji; Nosratollah Naderi; Bijan Moghimi-Dehkordi; Dariush Mirsattari; Hamid Mohaghegh Shalmani
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2013
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.